stocktrademan
9 years ago
$XNCR recent news/filings
bullish
## source: finance.yahoo.com
Fri, 12 Jun 2015 12:00:00 GMT ~ Xencor to Host R&D Day and Webcast on June 26, 2015
[PR Newswire] - MONROVIA, Calif., June 12, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, ...
read full: http://finance.yahoo.com/news/xencor-host-r-d-day-120000081.html
*********************************************************
Thu, 11 Jun 2015 20:17:48 GMT ~ XENCOR INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
read full: http://biz.yahoo.com/e/150611/xncr8-k.html
*********************************************************
Wed, 10 Jun 2015 12:32:02 GMT ~ Xencor Reports Complete Data Results on XmAb5871 Program at European League Against Rheumatism (EULAR) 2015 Annual Meeting
[at noodls] - MONROVIA, Calif., June 10, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, ...
read full: http://www.noodls.com/view/AA266D2A7FC4D8DB24C959D4C795C13E54201814
*********************************************************
Wed, 10 Jun 2015 12:01:19 GMT ~ XENCOR INC Files SEC form 8-K, Other Events
read full: http://biz.yahoo.com/e/150610/xncr8-k.html
*********************************************************
Wed, 10 Jun 2015 12:00:00 GMT ~ Xencor Reports Complete Data Results on XmAb5871 Program at European League Against Rheumatism (EULAR) 2015 Annual Meeting
[PR Newswire] - MONROVIA, Calif., June 10, 2015 /PRNewswire/ -- Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today reported complete data results from a Phase 1b/2a study of XmAb®5871 in patients with rheumatoid arthritis (RA). XmAb5871 was generally well tolerated and showed trends in improvement in RA disease activity by multiple disease activity measures and across multiple dose groups. "These data demonstrate clear signs of disease modifying activity in a patient population with active disease while on non-biologic disease modifying anti-rheumatic drug (DMARD) therapy," said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor.
read full: http://finance.yahoo.com/news/xencor-reports-complete-data-results-120000838.html
*********************************************************
$XNCR charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$XNCR company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/XNCR/company-info
Ticker: $XNCR
OTC Market Place: Not Available
CIK code: not found
Company name: Xencor, Inc.
Incorporated In:
$XNCR share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$XNCR extra dd links
Company name: Xencor, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=XNCR+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=XNCR+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=XNCR+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/XNCR/news - http://finance.yahoo.com/q/h?s=XNCR+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/XNCR/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/XNCR/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=XNCR+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/XNCR
DTCC (dtcc.com): http://search2.dtcc.com/?q=Xencor%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Xencor%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Xencor%2C+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/XNCR
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/XNCR/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/XNCR/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=XNCR&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=XNCR
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/XNCR/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=XNCR+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=XNCR+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=XNCR
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=XNCR
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=XNCR+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/XNCR/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=XNCR+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/XNCR.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=XNCR
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/XNCR/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/XNCR
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/XNCR
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/XNCR:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=XNCR
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=XNCR
$XNCR DD Notes ~ http://www.ddnotesmaker.com/XNCR
BayAreaBiotechI
10 years ago
XmAb7195 Questions
1. XmAb7195 engages the Fc?RIIb on B-cells to dampen IgE production. Bassil said it would take months to see an effect. Why does it take long? Shouldn't the B-cell be shut down immediately?
2. XmAb7195 engages the Fc?RIIb on liver sinusoidal endothelial cells, targeting IgE bound XmAb7195 to the liver for destruction, which was shown nicely by PET imaging in mice. IgG1 is a nice control, but it is not Xolair, like Bassil eluded to, it does not bind IgE. Bassil stated Xolair does not go to the liver, but I don't see any evidence of that, where is the data?
kbtoys
11 years ago
Translation to all fields of medicine
biologic therapies are already huge money makers. they are used in certain breast cancers, rheumatoid arthritis, ankylosing spondylitis, crohn's disease, certain lymphomas, etc. Imagine improving each of the current therapies for all of these conditions. at the very least, Xencor Inc could lease engineered Fc-fragment patents to each of these companies to improve their current therapy.
i see XNCR reaching ~$13-16 before any results are published. and depending on the results of current trials, this company could be worth billions.
News
Market Data
Register for streaming realtime charts, analysis tools, and prices.
Ask ADVFN Intelligence (AI)
Monksdream
6 months ago
